BACE-1

BACE-1

BACE-1 詳細

Molecule Name
Beta-secretase 1
分子の別称
BACE1,ASP2,BACE,FLJ90568,HSPC104,KIAA1149,Memapsin-2,Beta-Secretase,β-secretase
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
Beta-site amyloid precursor protein cleaving enzyme 1,KIAA1149,Asp 2,ASP2,Aspartyl protease 2,BACE,BACE1,Beta-Secretase 1,Membrane-Associated Aspartic Protease 2,Beta-Site APP-Cleaving Enzyme,Memapsin-2,Transmembrane Aspartic Proteinase Asp2,Beta-Site APP-Cleaving Enzyme 1,APP Beta-Secretase,EC 3.4.23.46,HSPC104,EC 3.4.23,Beta-Site APP Cleaving Enzyme 1,Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme,Beta-Secretase 1 Precursor Variant 1,EC:3.4.23.46
バックグランド
Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I  integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.

BACE-1 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
LanabecestatAZD-3293; LY-3314814Phase 3 ClinicalAstrazeneca Plc
Alzheimer Disease; Hepatic Insufficiency; Renal Insufficiency
詳細
ElenbecestatE-2609Phase 3 ClinicalEisai Co Ltd
Alzheimer Disease
詳細
TAK-070TAK-070Phase 1 ClinicalTakeda Pharmaceutical Co Ltd
Alzheimer Disease
詳細